Interferon-γ1b therapy in idiopathic pulmonary fibrosis -: A metaanalysis

被引:39
作者
Bajwa, EK
Ayas, NT
Schulzer, A
Mak, E
Ryu, JH
Malhotra, A
机构
[1] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA
[2] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V5Z 1M9, Canada
[4] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN USA
关键词
interferon; lung; pulmonary fibrosis; restriction; survival; treatment;
D O I
10.1378/chest.128.1.203
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Context: Despite the investigation of multiple therapeutic options, idiopathic pulmonary fibrosis (IPF) remains a devastating, progressively fatal disease. Much interest has focused on the use of interferon (IFN)-gamma 1b therapy, but the efficacy of this treatment has not been proven. Objective: To determine whether IFN treatment reduces mortality in patients with IPF. Design: A metaanalysis of randomized controlled trials evaluating the use of IFN-gamma 1b as treatment for IPF. Main outcome measure: Mortality in patients treated with IFN-gamma 1b was compared to mortality in patients treated with control therapies. Results: A total of three studies involving 390 patients was included in the analysis. IFN-gamma 1b therapy was associated with reduced mortality (hazard ratio [HR], 0.418; 95% confidence interval [CI], 0.253 to 0.690; p = 0.0003). A comparison of mortality at different time points revealed that IFN-gamma 1b therapy was associated with significantly reduced mortality at 1 year (0.0861; 95% CI, 0.0244 to 0.1478; p = 0.0063), 18 months (0.1682; 95% C1, 0.1065 to 0.2299; p < 0.0001), 650 days (0.1939; 95% C1, 0.1386 to 0.2492; p < 0.0001), and 2 years (0.2652; 95% CI, 0.1652 to 0.3652; p < 0.0001). Conclusion: When the results of multiple studies are combined in a metaanalysis, IFN-gamma 1b therapy is associated with reduced mortality.
引用
收藏
页码:203 / 206
页数:4
相关论文
共 22 条
[1]  
ANTONIOU KM, 2003, 99 INT C AM THOR SOC
[2]   Disorders of lung matrix remodeling [J].
Chapman, HA .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (02) :148-157
[3]   EFFECTS OF INTERFERON-GAMMA ON EXPRESSION OF CELL-SURFACE RECEPTORS FOR COLLAGEN AND DEPOSITION OF NEWLY SYNTHESIZED COLLAGEN BY CULTURED HUMAN-LUNG FIBROBLASTS [J].
CLARK, JG ;
DEDON, TF ;
WAYNER, EA ;
CARTER, WG .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (05) :1505-1511
[4]   Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis - A randomized prospective study [J].
Douglas, WW ;
Ryu, JH ;
Swensen, SJ ;
Offord, KP ;
Schroeder, DR ;
Caron, GM ;
DeRemee, RA ;
Fisk, DM ;
Krowka, MJ ;
Patel, AM ;
Schwartz, OA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (01) :220-225
[5]   Idiopathic pulmonary fibrosis - Impact of oxygen and colchicine, prednisone, or no therapy on survival [J].
Douglas, WW ;
Ryu, JH ;
Schroeder, DR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (04) :1172-1178
[6]   Expression of β-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells [J].
Duits, LA ;
Ravensbergen, B ;
Rademaker, M ;
Hiemstra, PS ;
Nibbering, PH .
IMMUNOLOGY, 2002, 106 (04) :517-525
[7]   Medical progress: Idiopathic pulmonary fibrosis. [J].
Gross, TJ ;
Hunninghake, GW .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (07) :517-525
[8]   Acute respiratory failure after interferon-γ therapy of end-stage pulmonary fibrosis [J].
Honoré, I ;
Nunes, H ;
Groussard, O ;
Kambouchner, M ;
Chambellan, A ;
Aubier, M ;
Valeyre, D ;
Crestani, B .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (07) :953-957
[9]   Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis [J].
Kalra, S ;
Utz, JP ;
Ryu, JH .
MAYO CLINIC PROCEEDINGS, 2003, 78 (09) :1082-1087
[10]   Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis [J].
Lukacs, NW ;
Hogaboam, C ;
Chensue, SW ;
Blease, K ;
Kunkel, SL .
CHEST, 2001, 120 (01) :5S-8S